THE US Federal Trade Commission (FTC) has sought additional information and documentary material related to Pfizer’s proposed acquisition of Seagen Inc , Seagen said on Friday (Jul 14).

The antitrust agency sent the requests separately to both the companies, a regulatory filing said.

Pfizer struck a US$43 billion deal in March to acquire Seagen and its targeted cancer therapies to counter the fall in Covid-related sales and generic competition for some top-selling drugs.

The recent scrutiny by the antitrust agency to block Amgen’s US$27.8 billion deal to buy Horizon Therapeutics has made investors jittery around the Pfizer-Seagen deal as well.

Seagan continues to expect its merger with Pfizer will be completed in late 2023 or early 2024, it said in the filing. REUTERS